Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

The chromatin remodeler hells regulates transcription-replication conflicts and genome integrity in ALK-negative anaplastic large cell lymphoma

Selene Mallia, Giulia Gambarelli, Veronica Manicardi, Benedetta Donati, Emanuele Vitale, Federica Torricelli, Elisa Salviato, Magda Zanelli, Noemi Puccio, Stefano Luminari, Francesco Merli, Antonino Neri, Alessia Ciarrocchi, Valentina Fragliasso

Blood (2025) 146 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2025-1477

Published: 2025

Journal Articles

Targeting hells‑mediated chromatin accessibility to sensitize ALK‑negative anaplastic large cell lymphoma to JAK/STAT and DNA‑PK inhibition

Giulia Gambarelli, Selene Mallia, Benedetta Donati, Noemi Puccio, Magda Zanelli, Emanuele Vitale, Federica Torricelli, Veronica Manicardi, Elisa Salviato, Stefano Luminari, Francesco Merli, Antonino Neri, Alessia Ciarrocchi, Valentina Fragliasso

Blood (2025) 146 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2025-1476

Published: 2025

Journal Articles

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

Blood (2025) 146 (Supplement 1): 5364.

https://doi.org/10.1182/blood-2025-5364

Published: 2025

Journal Articles

Morphology guided spatial transcriptomics to study topography of Hodgkin reed sternberg cells interaction with tumor microenvironment and its impact in defining risk of progression in classical Hodgkin lymphoma.

Benedetta Donati, Tanja Lazic, Riccardo Valli, Rexhep Durmo, Attilio Gennaro, Cristian Ascione, Pierluigi Di Chiaro, Alessia Ruffini, Manuel Gotti, Luca Arcaini, Erica Travaglino, Marco Paulli, Francesco Merli, Alessia Ciarrocchi, Stefano Luminari

Blood (2025) 146 (Supplement 1): 5315.

https://doi.org/10.1182/blood-2025-5315

Published: 2025

Journal Articles

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study

Rita Tavarozzi, Marco Ladetto, Francesca Bonello, Umberto Vitolo, Pier Luigi Zinzani, Angela Ferrari, Beatrice Casadei, Matthew Ku, Luigi Marcheselli, Stefano Luminari

Blood (2025) 146 (Supplement 1): 7096.

https://doi.org/10.1182/blood-2025-7096

Published: 2025

Journal Articles

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment

Ajay Gopal, Marek Trneny, Laurie Sehn, Julie Wu, Michael Arbushites, Oscar Bortolami, Stefano Luminari

Blood (2025) 146 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2025-1819

Published: 2025

Journal Articles

Utility of 18F-FDG PET/CT for response assessment in marginal zone lymphomas: Preliminary results of the IELSG44 international study

Luca Ceriani, Stefano Luminari, Anne Ségolène Cottereau, Rexhep Durmo, Luca Guerra, Annalisa Talami, Fabrizio Bergesio, Stephane Chauvie, Catherine Thieblemont, Emanuele Zucca

Blood (2025) 146 (Supplement 1): 1810.

https://doi.org/10.1182/blood-2025-1810

Published: 2025

Journal Articles

EPCORE FL-2 Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress

Paolo Strati, Philip Thompson, David Andorsky, Stefano Luminari, Kim Linton, Poliana Patah, Jian Mei, Neha Joshi, Neha Dixit, Elena Favaro, Emmanuel Bachy

Blood (2025) 146 (Supplement 1): 5393.

https://doi.org/10.1182/blood-2025-5393

Published: 2025

Journal Articles

Impact of 1q gain/amplification in multiple myeloma patients treated with daratumumab-based regimens: A retrospective single-center study

Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Alessia Tieghi, Stefano Luminari, Francesco Merli, Barbara Gamberi

Blood (2025) 146 (Supplement 1): 3976.

https://doi.org/10.1182/blood-2025-3976

Published: 2025

Journal Articles

Disruption of NEAT1-transcriptional network identifies targetable non-genetic dependencies in multiple myeloma

Noemi Puccio, Christian Boni, Federica Torricelli, Emanuele Vitale, Elisa Taiana, Domenica Ronchetti, Valentina Fragliasso, Selene Mallia, Giulia Gambarelli, Roberto Piva, Niccolo Bolli, Stefano Luminari, Alessia Ciarrocchi, Antonino Neri

Blood (2025) 146 (Supplement 1): 3945.

https://doi.org/10.1182/blood-2025-3945

Published: 2025

Journal Articles

Performance of radiomics features in patients with peripheral T-cell lymphoma: Data from international prospective T-cell project 2.0

Blood (2025) 146 (Supplement 1): 3651.

https://doi.org/10.1182/blood-2025-3651

Published: 2025

Journal Articles

Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL).

Blood (2025) 146 (Supplement 1): 5462.

https://doi.org/10.1182/blood-2025-5462

Published: 2025

Journal Articles

Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma

Blood (2025) 146 (Supplement 1): 3561.

https://doi.org/10.1182/blood-2025-3561

Published: 2025

Journal Articles

Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the fondazione italiana linfomi (FIL).

Blood (2025) 146 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2025-1004

Published: 2025

Journal Articles

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Blood (2024) 144 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2024-212970

Published: 2024

Journal Articles

The Prognostic Value of MTV Is Retained in New Proposed SUV 4 Threshold: An International Comparison of Follicular and Hodgkin Patient Survival

Stephane Chauvie, Luca Guerra, Federico Fallanca, Michele Gregianin, Annibale Versari, Rexhep Durmo, Fabrizio Bergesio, Adriano De Maggi, Enrica Bergalla, Alessandro Rambaldi, Simone Ferrero, Caterina Patti, Massimo Federico, Andrea Gallamini, Stefano Luminari

Blood (2024) 144 (Supplement 1): 6254.

https://doi.org/10.1182/blood-2024-206736

Published: 2024

Journal Articles

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2024-207886

Published: 2024

Journal Articles

Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Marco Ladetto, Rita Tavarozzi, Matthew Ku, Luca Arcaini, Carola Boccomini, Beatrice Casadei, Annalisa Chiarenza, Annarita Conconi, Ilaria Del Giudice, Michele Merli, Maria Elena Nizzoli, Stefano Luminari

Blood (2024) 144 (Supplement 1): 3042.1.

https://doi.org/10.1182/blood-2024-201305

Published: 2024

Journal Articles

Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry

Blood (2024) 144 (Supplement 1): 3076.

https://doi.org/10.1182/blood-2024-200259

Published: 2024

Journal Articles

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2024-202088

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The chromatin remodeler hells regulates transcription-replication conflicts and genome integrity in ALK-negative anaplastic large cell lymphoma

Targeting hells‑mediated chromatin accessibility to sensitize ALK‑negative anaplastic large cell lymphoma to JAK/STAT and DNA‑PK inhibition

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

Morphology guided spatial transcriptomics to study topography of Hodgkin reed sternberg cells interaction with tumor microenvironment and its impact in defining risk of progression in classical Hodgkin lymphoma.

Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment

Utility of 18F-FDG PET/CT for response assessment in marginal zone lymphomas: Preliminary results of the IELSG44 international study

EPCORE FL-2 Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress

Impact of 1q gain/amplification in multiple myeloma patients treated with daratumumab-based regimens: A retrospective single-center study

Disruption of NEAT1-transcriptional network identifies targetable non-genetic dependencies in multiple myeloma

Performance of radiomics features in patients with peripheral T-cell lymphoma: Data from international prospective T-cell project 2.0

Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL).

Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma

Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the fondazione italiana linfomi (FIL).

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

The Prognostic Value of MTV Is Retained in New Proposed SUV 4 Threshold: An International Comparison of Follicular and Hodgkin Patient Survival

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Frontline R-CHOP and BR Have Similar Outcomes By SUV max in Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only